Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue SUPPL.1, 2009, Pages 1-39

  Ebbesen, Peter ^a   Pettersen, Erik O ^b   Gorr, Thomas A ^c   Jobst, Gerhard ^d   Williams, Kaye ^e   Kieninger, Jochen ^f   Wenger, Roland H ^g   Pastorekova, Silvia ^h   Dubois, Ludwig ⁱ   Lambin, Philippe ⁱ   Wouters, Brad G ⁱ   Van Den Beucken, Twan ⁱ   Supuran, Claudiu T ^j   Poellinger, Lorenz ^k   Ratcliffe, Peter ^l   Kanopka, Arvydas ^m   Grlach, Agnes ⁿ   Gasmann, Max ^c   Harris, Adrian L ^l   Maxwell, Patrick ^o   Scozzafava, Andrea ^j   more..

^a AALBORG UNIVERSITY   (Denmark)

^b UNIVERSITY OF OSLO   (Norway)

^c VETSUISSE FACULTY UNIVERSITY OF ZURICH   (Switzerland)

^d JOBST TECHNOLOGIES GMBH   (Germany)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY OF ZURICH   (Switzerland)

^h INSTITUTE OF VIROLOGY   (Slovakia)

ⁱ MAASTRICHT UNIVERSITY   (Netherlands)

^j UNIVERSITY OF FLORENCE   (Italy)

^k KAROLINSKA INSTITUTE   (Sweden)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m VILNIUS UNIVERSITY   (Lithuania)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Antitumor drug; Carbonic anhydrase IX; Diagnostic agent; Enzyme inhibitors; HIF 1?; Hypoxia; Hypoxic tumor; Sulfonamide

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 NITROIMIDAZOLE; 4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; ANTIMETASTATIC AGENT; CARBOGEN; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; CARBOPLATIN; DOXORUBICIN; E 09; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INDOLE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA PRECURSOR; MITOMYCIN C; NICOTINAMIDE; NIMORAZOLE; OSTEOPONTIN; PIMONIDAZOLE; PR 104; PROTON PUMP INHIBITOR; RADIOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; SULFONAMIDE; TIRAPAZAMINE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTATION; CANCER CELL; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL CULTURE; CELL LABELING; CELL PROTECTION; CELLULAR STRESS RESPONSE; CHEMICAL REACTION; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GENE EXPRESSION PROFILING; HUMAN; HYPOXIA; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; MICROENVIRONMENT; NONHUMAN; OXIDATION REDUCTION REACTION; PH; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SENSOR; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR HYPOXIA; TUMOR RESISTANCE; TUMOR XENOGRAFT; UNFOLDED PROTEIN RESPONSE; ANIMAL; CELL HYPOXIA; DRUG DESIGN; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CELL HYPOXIA; DRUG DESIGN; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 66549090944     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360902784425     Document Type: Review

References (375)

1. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-6465
2. Mottram JC. Factor of importance in radiosensitivity of tumors. Br J Radiol 1936;9:606-614
3. Holthusen H. Beitrage zu Biologie der Strahlenwirkung. Pfluger's Arch. Ges. Physiol. 1921;187:1-24.
4. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-549
5. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-648
6. Adams GE, Dewey DL. Hydrated electrons and radiobiological sensitization. Biochem Biophys Res Commun 1963;12:473-477
7. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13:139-168
8. Cosse JP, Michiels C. Tumor hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008;8(7):790-797
9. Hill RP, Stanley JA. The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents. Cancer Res 1975; 35:1147-1153
10. Adams GE. Hypoxic cell sensitizers for radiotherapy. Int J Radiat Oncol Biol Phys 1978;4:135-141
11. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 1997;147:541-550
12. Adams GE. Failla Memorial Lecture.Redox, radiation, and reductive bioactivation. Radiat Res 1992;132:129-139
13. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402.
14. Holmquist-Mengelbier L, Fredlund E, Löfstedt T, Noguera R, Navarro S, Nilsson H, et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006;10:413-423
15. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008 May 23;30(4):393-402.
16. Wolfbeis OS, Leiner MJP, Posch HE. A new sensing material for optical oxygen measurement, with the indicator embedded in an aqueous phase. Microchim Acta 1986;90(5):359-366
17. Lippitsch ME, Pusterhofer J, Leiner MJP, Wolfbeis OS. Fibre-optic oxygen sensor with the fluorescence decay time as the information carrier. Anal Chim Acta 1988;205:1-6.
18. Martinez-Manez R, Soto J, Lizondo-Sabater J, Garcia-Breijo E, Gil L, Ibanez J, et al. New potentiometric dissolved oxygen sensors in thick film technology. Sens Actuators B Chem 2004;101:295-301.
19. Clark LC Jr, Wolf R, Granger D, Taylor Z. Continuous recording of blood oxygen tensions by polarography. J Appl Physiol 1953;6(3):189-193
20. Jobst G, Urban G, Jachimowicz A, Kohl F, Tilado O. Thin-film Clark-type oxygen sensor-based on novel polymer membrane systems for in-vivo and biosensor applications. Biosens Bioelectron 1993;8(3-4):123-128
21. Kieninger J, Dannenberg A, Aravindalochanan A, Jobst G, Pettersen EO, Urban GA. Amperometric oxygen sensor array with novel chronoamperometric protocols for hypoxic tumor cell cultures. Presented at the International Conference on Solid-State Sensors, Actuators and Microsystems Conference, 2007: Transducers 2007, Lyon, France, pp 1907-1910
22. Wittkampf M, Chemnitius G-C, Cammann K, Rospert M, Mokwa W. Silicon thin film sensor for measurement of dissolved oxygen. Sens Actuators B Chem 1997;43:40-44
23. Brischwein M, Motrescu ER, Cabala E, Otto AM, Grothe H, Wolf B. Functional cellular assays with multiparametric silicon sensor chips. Lab Chip 2003;3(4):234-240
24. Pettersen EO, Larsen LH, Ramsing NB, Ebbesen P. Pericellular oxygen depletion during ordinary tissue culturing, measured with oxygen microsensors. Cell Prolif 2005;38:257-267
25. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumor regression. Nature 2006;441:437-443
26. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-684
27. Semenza GL. Life with oxygen. Science 2007;318:62-64
28. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005;(306):re12.
29. Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nature Chem Biol 2008;4:152-156
30. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004;5:343-354
31. Koivunen P, Tiainen P, Hyvarinen J, Williams KE, Sormunen R, Klaus SJ, et al. An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha. J Biol Chem 2007;282:30544-30552
32. Clifton IJ, McDonough MA, Ehrismann D, Kershaw NJ, Granatino N, Schofield CJ. Structural studies on 2-oxoglutarate oxygenases and related double-stranded beta-helix fold proteins. J Inorganic Biochem 2006;100:644-669
33. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor HIF. J Biol Chem 2003;278:30772-30780
34. Koivunen P, Hirsilä M, Günzler V, Kivirikko KI, Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem. 2004 Mar 12;279(11):9899-9904
35. Tuckerman JR, Zhao Y, Hewitson KS, Tian YM, Pugh CW, Ratcliffe PJ, et al. Determination and comparison of specific activity of the HIF-prolyl hydroxylases. FEBS Lett 2004;576:145-150
36. Ehrismann D, Flashman E, Genn DN, Mathioudakis N, Hewitson KS, Ratcliffe PJ, et al. Studies on the activity of the hypoxia-inducible factor hydroxylases using an oxygen consumption assay. Biochem J 2007;401:227-234
37. Koivunen P, Hirsila M, Kivirikko KI, Myllyharju J. The length of peptide substrates has a marked effect on hydroxylation by the hypoxia-inducible factor prolyl 4 hydroxylases. J Biol Chem 2006;281:28712-28720
38. Chan DA, Sutphin PD, Denko NC, Giaccia AJ. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1a. J Biol Chem 2002;277:40112-40117
39. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 2004;118:781-794
40. Knowles HJ, Raval RR, Harris AL, Ratcliffe PJ. Effect of ascorbate on the activity of hypoxia inducible factor (HIF) in cancer cells. Cancer Res 2003; 63:1764-1768
41. Smith TG, Balanos GM, Croft QPP, Talbot NP, Dorrington KL, Ratcliffe PJ, et al. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 2008;586:5999-6005.
42. Dalgard CL, Lu H, Mohyeldin A, Verma A. Endogenous 2-oxoacids differentially regulate expression of oxygen sensors. Biochem J 2004; 380:419-424
43. Hewitson KS, Lienard BM, McDonough MA, Clifton IJ, Butler D, Soares AS, et al. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem 2007;282:3293-3301
44. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Merino M, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005;8:143-153
45. Koivunen P, Hirsila M, Remes AM, Hassinen IE, Kivirikko KI, Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 2007;282:4524-4532
46. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005;7:77-85.
47. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumors which result from germline FH and SDH mutations. Hum Mol Genet 2005;14:2231-2239
48. Mackenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, Frederiksen CM, et al. Cell permeating alpha-ketoglutarate derivatives alleviate pseudo-hypoxia in SDH deficient cells. Mol Cell Biol 2007;27:3282-3289
49. Knowles HJ, Mole DR, Ratcliffe PJ, Harris AL. Normoxic stabilization of hypoxia-inducible factor-1alpha by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistance-associated macrophage protein 1. Cancer Res 2006;66:2600-2607
50. Pagé EL, Chan DA, Giaccia AJ, Levine M, Richard DE. Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell. 2008 Jan;19(1):86-94.
51. Vissers MC, Gunningham SP, Morrison MJ, Dachs GU, Currie MJ. Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate. Free Radic Biol Med 2007;42:765-772
52. Kietzmann T, Görlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin Cell Dev Biol 2005;16:474-486
53. Pan Y, Mansfield KD, Bertozzi CC, Rudenko V, Chan DA, Giaccia AJ, et al. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol 2007;27:912-925
54. Bell EL, Klimova TA, Eisenbart J, Moraes CT, Murphy MP, Budinger GR, et al. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signalling via reactive oxygen species production. J Cell Biol 2007;177:1029-1036
55. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab. 2005 Jun;1(6):401-408
56. Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. Loss of the SdhB, but not the SdhA, subunit of complex II triggers reactive oxygen speciesdependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 2008;28:718-731
57. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab 2005;1:393-399
58. Matlin AJ, Clark F, Smith CWJ. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005;6:386-398
59. Kramer A. The structure and function of proteins involved in mammalian pre-mRNA splicing. Annu Rev Biochem 1996;65:367-409.
60. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003;17:419-437
61. Srebrow A, Kornblihtt AR. The connection between splicing and cancer. J Cell Sci 2006;119:2635-2641
62. Kalnina Z, Zyakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 2005;42:342-357
63. Veneables JP. Abberant and alternative splicing in cancer. Cancer Res 2004;64:7647-7654
64. Stoss O, Stoilov P, Daoud R, Hartmann AM, Olbrich M, Stamm S. Misregulation of pre-mRNA splicing that causes human diseases. Concepts and therapeutic strategies. Gene Ther Mol Biol 2000; 5:9-30.
65. Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC. Mechanism for elimination of a tumor suppresor: aberant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci USA 1999;96:9689-9694
66. Semenza G. HIF-1 and human disease: one highly involved factor. Genes Dev 2000;14:1983-1991
67. Semenza G. Targeting HIF-1 for cancer therapy. Nat Rev 2003;3:721-732
68. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, et al. Inhibitory PAS domain protein is a negative regulator of hypoxiainducible gene expression. Nature 2001;414:550-554
69. Yamashita T, Ohneda O, Nagano M, Iemitsu M, Makino Y, Tanaka H, et al. Abnormal heart development and lung remodeling in mice lacking the hypoxia-inducible factor-related basic helix-loop-helix PAS protein NEPAS. Mol Cell Biol 2008;28:1285-1297
70. Gothie E, Richard DE, Berra E, Pages G, Pouyssegur J. Identification of alternatively spliced variants of human hypoxia-inducible factor-1?. J Biol Chem 2000;275:6922-7.
71. Chun Y-S, Choi E, Kim T-Y, Kim M-S, Park J-W. A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor- 1? gene. Biochem J 2002;362:71-79
72. Maynard MA, Qi H, Chung J, Lee EHL, Kondo Y, Hara S, et al. Multiple splice variants of the human HIF-3α locus are targets of the von Hippel- Lindau E3 ubiquitin ligase complex. J Biol Chem 2003;278:11032-11040
73. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 2002;277:32405-32408
74. Barathova M, Takacova M, Holotnakova T, Gibadulinova A, Ohradanova A, Zatovicova M, et al. Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumor phenotype. Br J Cancer 2008;98:129-136
75. Wouters BG, van den Beucken T, Magagnin MG, Lambin P, Koumenis C. Targeting hypoxia tolerance in cancer. Drug Resist Updat 2004; 7(1):25-40.
76. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 2004;4(6):437-447
77. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001;28(2 Suppl 8):36-41.
78. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008;8(11):851-864
79. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004;18(23):2893-2904
80. Connolly E, Braunstein S, Formenti S, Schneider RJ. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol 2006;26(10):3955-3965
81. Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC. Hypoxiainduced energy stress regulates mRNA translation and cell growth. Mol Cell 2006;21(4):521-531
82. Koritzinsky M, Rouschop KM, van den Beucken T, Magagnin MG, Savelkouls K, Lambin P, et al. Phosphorylation of eIF2alpha is required for mRNA translation inhibition and survival during moderate hypoxia. Radiother Oncol 2007;83(3):353-361
83. Magagnin MG, van den Beucken T, Sergeant K, Lambin P, Koritzinsky M, Devreese B, et al. The mTOR target 4E-BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency. Proteomics 2008;8(5):1019-1028
84. Weppler SA, Krause M, Zyromska A, Lambin P, Baumann M, Wouters BG. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol 2007;82(1):96-104.
85. Koumenis C, Naczki C, Koritzinsky M, Rastani S, Diehl A, Sonenberg N, et al. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol 2002;22(21):7405-7416
86. Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, et al. ER stressregulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J 2005;24(19):3470-3481
87. Koritzinsky M, Magagnin MG, van den Beucken T, Seigneuric R, Savelkouls K, Dostie J, et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J 2006;25(5):1114-1125
88. Koritzinsky M, Seigneuric R, Magagnin MG, van den Beucken T, Lambin P, Wouters BG. The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol 2005;76(2):177-186
89. van den Beucken T, Magagnin MG, Savelkouls K, Lambin P, Koritzinsky M, Wouters BG. Regulation of Cited2 expression provides a functional link between translational and transcriptional responses during hypoxia. Radiother Oncol 2007;83(3):346-352
90. Magagnin MG, Sergeant K, van den Beucken T, Rouschop KM, Jutten B, Seigneuric R, et al. Proteomic analysis of gene expression following hypoxia and reoxygenation reveals proteins involved in the recovery from endoplasmic reticulum and oxidative stress. Radiother Oncol 2007;83(3):340-345
91. Goetz ME, Luch A. Reactive species: a cell damaging rout assisting to chemical carcinogens. Cancer Lett 2008;266:73-83.
92. Lu W, Ogasawara MA, Huang P. Models of reactive oxygen species in cancer. Drug Discov Today Dis Models 2007;4:67-73.
93. Lenart J, Dombrowski F, Görlach A, Kietzmann T. Deficiency of manganese superoxide dismutase in hepatocytes disrupts zonated gene expression in mouse liver. Arch Biol Biophys 2007;462:238-244
94. Hervouet E, Simonnet H, Godinot C. Mitochondria and reactive oxygen species in renal cancer. Biochimie 2007;89:1080-1088
95. Penta JS, Johnson FM, Wachsman JT, Copeland WC. Mitochondrial DNA in human malignancy. Mutat Res, 2001;488:119-133
96. Sarti P, Avigliano L, Görlach A, Brüne B. Superoxide and nitric oxide- participation in cell communication. Cell Death Differ 2002;9:1160-1162
97. Görlach A, Kietzmann T, Hess J. Redox signaling through NADPH oxidases - involvement in vascular proliferation and coagulation. Ann NY Acad Sci 2002;973:505-507
98. Forman HJ, Fukuto JM, Miller T, Zhang H, Rinna A, Levy S. The chemistry of cell signaling by reactive oxygen and nitrogen species and 4-hydroxynonenal. Arch Biochem Biophys 2008;477:183-195
99. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006;7:833-846
100. Clerkin JS, Naughton R, Quiney C, Cotter TG. Mechanisms of ROS modulated cell survival during carcinogenesis. Cancer Lett 2008;266:30-36
101. Görlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, et al. Thrombin activates the HIF-1 signaling pathway in vascular smooth muscle cells. Role of the p22phox-containing NADPH oxidase. Circ Res 2001;89:47-54. (Pubitemid 34135491)
102. Görlach A, Kietzmann T. Superoxide and derived reactive oxygen species in the regulation of hypoxia-inducible factors. Methods Enzymol 2007;435:421-446
103. Bonello S, Zähringer C, BelAiba RS, Djordjevic T, Hess J, Michiels C, et al. Reactive oxygen species activate the HIF-1α promoter via a functional NFκB site. Arterioscler Thromb Vasc Biol 2007;27:755-761
104. BelAiba RS, Bonello S, Schmidt S, Diemer K, Kietzmann T, Hess J, et al. Hypoxia-induced HIF-1α mRNA level is mediated by NFκB via PI3K/AKT pathway activation in pulmonary artery smooth muscle cells. Mol Biol Cell 2007;18:4691-4697
105. Lambeth JD. NOX enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 2007;43:332-347
106. Rokutan K, Kawahara T, Kuwano Y, Tominaga K, Sekiyama A, Teshima- Kondo S. NADPH oxidases in the gastrointestinal tract: a potential role of Nox1 in innate immune response and carcinogenesis. Antioxid Redox Signal 2006;8(9-10):1573-1582
107. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res 2006;71:226-235
108. Otani H. Reactive oxygen species as mediators of signal transduction in ischemic preconditioning. Antioxid Redox Signal 2004;6:449-469
109. Lambeth JD, Krause KH, Clark RA. NOX enzymes as novel targets for drug development. Semin Immunopathol 2008;30:339-363
110. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8:425-437
111. Robinson JM. Reactive oxygen species in phagocytic leukocytes. Histochem Cell Biol 2008;130:281-297
112. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008;99:1501-1506
113. BelAiba RS, Djordjevic T, Bonello S, Flügel D, Hess J, Kietzmann T, et al. Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells. Biol Chem 2004;385:249-257 (Pubitemid 38679070)
114. BelAiba RS, Djordjevic T, Petry A, Diemer K, Bonello S, Banfi B, et al. NOX5 variants are functionally active in endothelial cells. Free Rad Biol Med 2007;42:446-459
115. Brahimi-Horn MC, Pouysségur J. Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem 2007;43:165-178
116. Walenta S, Mueller-Klieser WF. Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol 2004;14:267-274
117. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 2002;8:1284-1291
118. Stubbs M, McSheehy PMJ, Griffiths JR, Bashford CL. Causes and consequences of tumor acidity and implications for treatment. Mol Med Today 2000;6:15-19.
119. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumors. Br J Radiol 2003;76:S11-22.
120. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075-7083
121. Pastorekova S, Casini A, Scozzafava A, Vullo D, Pastorek J, Supuran CT. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14:869-873 (Pubitemid 38167605)
122. Potter CP, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003;89:2-7.
123. Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, et al. Cloning and characterisation of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and putative helix-loop-helix DNA binding segment. Oncogene 1994;9:2877-2888
124. Pastorekova S, Ratcliffe PJ, Pastorek J. Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int 2008;101(Suppl 4):8-15.
125. Svastova E, Hulikova A, Rafajova M, Zatovicova M, Gibadulinova A, Casini A, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004;577:439-445
126. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007; 26:299-310.
127. Swietach P, Wigfield S, Cobden P, Supuran CT, Harris AL, Vaughan- Jones RD. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem 2008;283:20473-20483
128. Dubois L, Douma K, Supuran CT, Chiu RK, van Zandvoort MA, Pastoreková S, et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol 2007;83:367-373
129. Rafajova M, Zatovicova M, Kettmann R, Pastorek J, Pastorekova S. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol 2004;24:995-1004.
130. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, et al. Cellular and developmental control of O2 homeostasis by hypoxiainducible factor 1?. Genes Dev 1998;12:149-162
131. Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 2008;14: 685-698
132. Görlach A, Camenisch G, Kvietikova I, Vogt L, Wenger RH, Gassmann M. Efficient translation of mouse hypoxia-inducible factor-1α under normoxic and hypoxic conditions. Biochim Biophys Acta 2000;1493:125-134
133. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007;129:111-122
134. Wenger RH. Mitochondria: oxygen sinks rather than sensors? Med Hypoth 2006;66:380-383
135. Stiehl DP, Wirthner R, Köditz J, Spielmann P, Camenisch G, Wenger RH. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels.Evidence for an autoregulatory oxygen-sensing system. J Biol Chem 2006;281:23482-23491
136. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-185
137. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006;3:187-197
138. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHLdeficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007;11:407-420
139. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 2008;283:10892-10903
140. Blais JD, Filipenko V, Bi M, Harding HP, Ron D, Koumenis C, et al. Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol 2004;24:7469-7482
141. Köditz J, Nesper J, Wottawa M, Stiehl DP, Camenisch G, Franke C, et al. Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 2007;110:3610-3617
142. Pettersen EO, Lindmo T. Inhibition of cell-cycle progression by acute treatment with various degrees of hypoxia: modifications induced by low concentrations of misonidazole present during hypoxia. Br J Cancer 1983;48:809-817
143. Åmellem O, Stokke T, Sandvik JA, Pettersen EO. The retinoblastoma gene product is reversibly dephosphorylated and bound in the nucleus in S and G2 phase during hypoxic stress. Exp Cell Res 1996;227:106-115
144. Åmellem O, Stokke T, Sandvik JA, Karlsen F, Pettersen EO. The retinoblastoma protein-associated cell cycle arrest in S-phase under moderate hypoxia is disrupted in cells expressing HPV18 E7 oncoprotein. Br J Cancer 1998;77:862-872
145. Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang CV. Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem. 2001 Mar 16;276(11):7919-7926
146. Krtolica A, Krucher NA, Ludlow JW. Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities. Oncogene 1998;17:2295-2304
147. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003;23:359-369
148. Graff P, Seim J, Amellem Ø, Arakawa H, Nakamura Y, Andersson KK, Stokke T, Pettersen EO. Counteraction of pRb-dependent protection after extreme hypoxia by elevated ribonucleotide reductase. Cell Prolif. 2004 Oct;37(5):367-383
149. Green SL, Freiberg RA, Giaccia AJ. p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxiainduced arrest. Mol Cell Biol 2001;21:1196-1206
150. Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ Jr, Giaccia AJ. Hypoxia induces accumulation of p53 protein, but activation of a G1- phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994;14:6264-6277
151. Pettersen EO, Lindmo T. Inhibition of cell-cycle progression by acute treatment with various degrees of hypoxia: modifications induced by low concentrations of misonidazole present during hypoxia. Br J Cancer. 1983 Dec;48(6):809-817
152. Åmellem O, Pettersen EO. The role of protein accumulation on the kinetics of entry into S phase following extreme hypoxia. Anticancer Res 1991;11:1083-1087
153. Åmellem O, Pettersen EO. Cell inactivation and cell cycle inhibition as induced by extreme hypoxia: the possible role of cell cycle arrest as a protection against hypoxia-induced lethal damage. Cell Prolif 1991;24:127-141
154. Åmellem O, Löffler M, Pettersen EO. Regulation of cell proliferation under extreme and moderate hypoxia: the role of pyrimidine (deoxy) nucleotides. Br J Cancer 1994;70:857-866
155. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 1995;92:12146-12150
156. Probst G, Riedinger HJ, Martin P, Engelcke M, Probst H. Fast control of DNA replication in response to hypoxia and to inhibited protein synthesis in CCRF-CEM and HeLa cells. Biol Chem 1999;380:1371-1382
157. Ludlow JW, Howell RL, Smith HC. Hypoxic stress induces reversible hypophosphorylation of pRb and reduction in cyclin A abundance independent of cell-cycle progression. Oncogene 1993;8:331-339
158. Krtolica A, Ludlow JW. Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected. Cancer Res 1996;56:1168-1173
159. Graff P, Åmellem Ø, Andersson KK, Pettersen EO. Role of ribonucleotide reductase in regulation of cell cycle progression during and after exposure to moderate hypoxia. Anticancer Res 2002;22:59-68.
160. Thelander L, Reichard P. Reduction of ribonucleotides. Annu Rev Biochem 1979;48:133-158
161. Eklund H, Uhlin U, Färnegårdh M, Logan DT, Nordlund P. Structure and function of the radical enzyme ribonucleotide reductase. Prog Biophys Mol Biol 2001;77:177-268.
162. Bianchi V, Borella S, Calderazzo F, Ferraro P, Chieco BL, Reichard P. Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl Acad Sci USA 1994;91:8403-8407
163. Nocentini G. Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Crit Rev Oncol Hematol 1996;22:89-126.
164. Holland KP, Elford HL, Bracchi V, Annis CG, Schuster SM, Chakrabarti D. Antimalarial activities of polyhydroxyphenyl and hydroxamic acid derivatives. Antimicrob Agents Chemother 1998;42:2456-2458
165. Guppy M, Withers P. Metabolic depression in animals: physiological perspectives and biochemical generalizations. Biol Rev Camb Philos Soc 1999;74:1-40.
166. Gorr TA, Gassmann M, Wappner P. Sensing and responding to hypoxia via HIF in model invertebrates. J Insect Physiol 2006;52:349-364
167. Hochachka PW, Buck LT, Doll CJ, Land SC. Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA 1996;93:9493-9498
168. Boutilier RG. Mechanisms of cell survival in hypoxia and hypothermia. J Exp Biol 2001;204:3171-3181
169. Boutilier RG, Donohoe PH, Tattersall GJ, West TG. Hypometabolic homeostasis in overwintering aquatic amphibians. J Exp Biol. 1997 Jan;200(Pt 2):387-400.
170. Rolfe DF, Brown GC. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev 1997;77:731-758
171. Land SC, Buck LT, Hochachka PW. Response of protein synthesis to anoxia and recovery in anoxia-tolerant hepatocytes. Am J Physiol 1993;265:R41-8.
172. Land SC, Hochachka PW. Protein turnover during metabolic arrest in turtle hepatocytes: role and energy dependence of proteolysis. Am J Physiol 1994;266:C1028-36.
173. Buck LT, Hochachka PW. Anoxic suppression of Na(+)-K(+)-ATPase and constant membrane potential in hepatocytes: support for channel arrest. Am J Physiol 1993;265:R1020-5.
174. Krumschnabel G, Schwarzbaum PJ, Lisch J, Biasi C, Wieser W. Oxygendependent energetics of anoxia-tolerant and anoxia-intolerant hepatocytes. J Exp Biol 2000;203:951-959
175. Storey K. A re-evaluation of the Pasteur effect: new mechanisms in anaerobic metabolism. Mol Physiol 1985;8:439-461
176. Schmidt H, Kamp G. The Pasteur effect in facultative anaerobic metazoa. Experientia 1996;52:440-448
177. Padilla PA, Roth MB. Oxygen deprivation causes suspended animation in the zebrafish embryo. Proc Natl Acad Sci USA 2001;98:7331-7335
178. Padilla PA, Nystul TG, Zager RA, Johnson AC, Roth MB. Dephosphorylation of cell cycle-regulated proteins correlates with anoxia-induced suspended animation in Caenorhabditis elegans. Mol Biol Cell 2002;13:1473-1483
179. Froese G. The respiration of ascites tumor cells at low oxygen concentrations. Biochim Biophys Acta 1962;57:509-519
180. Freyer JP. Rates of oxygen consumption for proliferating and quiescent cells isolated from multicellular tumor spheroids. Adv Exp Med Biol 1994;345:335-342
181. Pettersen EO, Lindmo T. Inhibition of cell-cycle progression by acute treatment with various degrees of hypoxia: modifications induced by low concentrations of misonidazole present during hypoxia. Br J Cancer. 1983;48:809-817.
182. Probst H, Schiffer H, Gekeler V, et al. Oxygen dependent regulation of DNA synthesis and growth of Ehrlich ascites tumor cells in vitro and in vivo. Cancer Res 1988;48:2053-2060
183. Pettersen EO, Juul NO, Ronning OW. Regulation of protein metabolism of human cells during and after acute hypoxia. Cancer Res 1986;46:4346-4351
184. Kraggerud SM, Sandvik JA, Pettersen EO. Regulation of protein synthesis in human cells exposed to extreme hypoxia. Anticancer Res 1995;15:683-686
185. Guppy M, Brunner S, Buchanan M. Metabolic depression: a response of cancer cells to hypoxia? Comp Biochem Physiol B Biochem Mol Biol 2005;140:233-239
186. Giaccia AJ. Hypoxic stress proteins: survival of the fittest. Semin Radiat Oncol 1996;6:46-58.
187. Freyer JP, Sutherland RM. A reduction in the in situ rates of oxygen and glucose consumption of cells in EMT6/Ro spheroids during growth. J Cell Physiol 1985;124:516-524
188. Eskey CJ, Koretsky AP, Domach MM, Jain RK. Role of oxygen vs.glucose in energy metabolism in a mammary carcinoma perfused ex vivo: direct measurement by 31P NMR. Proc Natl Acad Sci USA 1993;90:2646-2650
189. Walenta S, Doetsch J, Mueller-Klieser W, Kunz-Schughart LA. Metabolic imaging in multicellular spheroids of oncogene-transfected fibroblasts. J Histochem Cytochem 2000;48:509-522
190. Kunz-Schughart LA, Freyer JP. Phosphorous metabolites and steadystate energetics of transformed fibroblasts during three-dimensional growth. Am J Physiol Cell Physiol 2002;283:C1287-97.
191. Zölzer F, Stüben G, Knühmann K, Streffer C, Sack H. Quiescent S-phase cells as indicators of extreme physiological conditions in human tumor xenografts. Int J Radiat Oncol Biol Phys 1999;45:1019-1024
192. Masunaga S, Ono K, Takahashi A, Ohnishi T, Kinashi Y, Takagaki M. Radiobiological characteristics of solid tumors depending on the p53 status of the tumor cells, with emphasis on the response of intratumor quiescent cells. Eur J Cancer 2002;38:718-727 (Pubitemid 34251397)
193. Masunaga S, Uto Y, Nagasawa H, Hori H, Nagata K, Suzuki M, et al. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells. Anticancer Res 2006;26:1261-1270
194. Dubois L, Magagnin MG, Cleven AH, Weppler SA, Grenacher B, Landuyt W, Lieuwes N, Lambin P, Gorr TA, Koritzinsky M, Wouters BG. Inhibition of 4E-BP1 Sensitizes U87 Glioblastoma Xenograft Tumors to Irradiation by Decreasing Hypoxia Tolerance. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1219-1227
195. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2(1):38-47.
196. Beasley NJ, Wykoff CC, Watson PH, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001;61(13):5262-5267
197. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001;7(8):345-350
198. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92(12):5510-5514
199. Gustafsson MV, Zheng X, Pereira T, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005;9(5):617-628
200. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Upregulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005;65(19):8690-8697
201. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10(8):789-799
202. Huang LE, Bindra RS, Glazer PM, Harris AL. Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J Mol Med 2007;85(2):139-148
203. Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, White E. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes & development 2004;18(17):2095-2107
204. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379(6560):88-91.
205. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer metastasis reviews 2007;26(2):333-339
206. Gort EH, Groot AJ, van der Wall E, van Diest PJ, Vooijs MA. Hypoxic regulation of metastasis via hypoxia-inducible factors. Current molecular medicine 2008;8(1):60-67
207. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008;8(7):790-797
208. Charlesworth PJ, Harris AL. Mechanisms of disease: angiogenesis in urologic malignancies. Nature clinical practice 2006;3(3):157-169
209. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006;24(5):727-735
210. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. British journal of cancer 2003;89(5):877-885
211. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway-a report of the Tumour Angiogenesis Research Group. J Clin Oncol 2006;24(26):4301-4308
212. Marignol L, Coffey M, Lawler M, Hollywood D. Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev 2008;34(4):313-327
213. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003;22(21):3213-3220
214. Song X, Liu X, Chi W, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF- 1alpha gene. Cancer chemotherapy and pharmacology 2006;58(6):776-784
215. Sermeus A, Cosse JP, Crespin M, et al. Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer 2008;7:27.
216. Moeller BJ, Dewhirst MW. HIF-1 and tumor radiosensitivity. Br J Cancer 2006;95(1):1-5.
217. Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005;8(2):99-110.
218. Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, Inoue M, et al. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 2007;26(54):7508-7516
219. Williams KJ, Telfer BA, Xenaki D, et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 2005;75(1):89-98.
220. Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002;38:240-257
221. Adam MF, Gabalski EC, Bloch DA, Oehlert JW, Brown JM, Elsaid AA, et al. Tissue oxygen distribution in head and neck cancer patients. Head Neck 1999;21(2):146-153
222. Stadler P, Becker A, Feldmann HJ, Hansgen G, Dunst J, Wurschmidt F, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44(4):749-754
223. Raleigh JA, Chou SC, Calkins-Adams DP, Ballenger CA, Novotny DB, Varia MA. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Clin Cancer Res 2000;6(3):855-862
224. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen JA, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-7074
225. Gross MW, Karbach U, Groebe K, Franko AJ, Mueller-Klieser W. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer 1995;61(4):567-573
226. Nordsmark M, Loncaster J, Aquino-Parsons C, Chou SC, Ladekarl M, Havsteen H, et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol 2003;67(1):35-44.
227. Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001;61(13):5262-5267
228. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of the hypoxia-inducible factors HIF- 1alpha and HIF-2alpha in normal human tissues, cancers, and tumorassociated macrophages. Am J Pathol 2000;157(2):411-421
229. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59(22):5830-5835
230. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005;11(3):1129-1135
231. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, et al. Hypoxia-regulated carbonic anhydrase-9 (CA IX) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001;7(11):3399-3403
232. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001;61(21):7992-7998
233. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003;21(3):473-482
234. Loncaster JA, Harris AL, Davidson SE, Loque JP, Hunter RD, Wykoff CC, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61(17):6394-6399
235. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001;19(16):3660-3668
236. Hutchison GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA, et al. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 2004;10(24):8405-8412
237. Mayer A, Hockel M, Vaupel P. Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin Cancer Res 2005;11(20):7220-7225
238. Mayer A, Wree A, Hockel M, Leo C, Pilch H, Vaupel P. Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res 2004;64(16):5876-5881
239. Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raleigh JA, Lerman MI, et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 2001;61(24):8924-8929
240. Janssen HL, Haustermans KM, Sprong D, Blommestijn G, Hofland I, Hoebers FJ, et al. HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 2002;54(5):1537-1549
241. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003;9(1):59-67.
242. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005;6(10):757-764
243. Krause BJ, Beck R, Souvatzoglou M, Piert M. PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging 2006;50(1):28-43.
244. Bucca G, Carruba G, Saetta A, Muti P, Castagnetta L, Smith CP. Gene expression profiling of human cancers. Ann NY Acad Sci 2004;1028:28-37.
245. Choi P, Chen C. Genetic expression profiles and biologic pathway alterations in head and neck squamous cell carcinoma. Cancer 2005;104(6):1113-1128
246. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)- toward standards for microarray data. Nat Genet 2001;29(4):365-371
247. Akervall J. Gene profiling in squamous cell carcinoma of the head and neck. Cancer Metastasis Rev 2005;24(1):87-94.
248. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5(5):489-500.
249. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102(10):3738-3743
250. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006;3(3):e47.
251. Nuyten DS, Kreike B, Hart AA, Chi JT, Sneddon JB, Wessels LF, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006;8(5):R62.
252. Francis P, Namlos HM, Muller C, Eden P, Fernebro J, Berner JM, et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007;8:73.
253. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, et al. hsamiR- 210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008;14(5):1340-1348
254. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, et al. HIF activation identifies early lesions in VHL kidneys.Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002;1:459-468
255. Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, et al. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002;13:1721-1732
256. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005;25:5675-5686
257. Esteban MA, Harten SK, Tran MG, Maxwell PH. Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. J Am Soc Nephrol 2006;17:1801-1806
258. Harten SK, Shukla D, Barod R, Hergovich A, Balda MS, Matter K, et al. Repression of occludin and claudin 1 contributes to tight junction abnormalities in von Hippel-Lindau defective renal cancer cells. Mol Biol Cell 2009;20:1089-1101
259. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-1416
260. Sutherland RM, Ausserer WA, Murphy BJ, Laderoute KR. Tumor hypoxia and heterogeneity: challenges and opportunities for the future. Semin Radiat Oncol 1996;6:59-70.
261. Koch CJ. Oxygen effects in radiobiology. Adv Exp Med Biol 1982;157:123-144
262. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-289
263. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515
264. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84:1070-1075
265. Vaupel P, Thews O, Kelleher DK, Hoeckel M. Oxygenation of human tumors: the Mainz experience. Strahlenther Onkol 1998;174 (Suppl 4):6-12.
266. Magagnin MG, Koritzinsky M, Wouters BG. Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxiadirected therapies. Drug Resist Updat. 2006 Aug-Oct;9(4-5):185-197
267. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757.
268. Bussink J, Kaanders JH, Strik AM, Vojnovic B, van der Kogel AJ. Optical sensor-based oxygen tension measurements correspond with hypoxia marker binding in three human tumor xenograft lines. Radiat Res 2000;154:547-555
269. Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991;51:3316-3322
270. Koch CJ. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol 2002;352:3-31.
271. Raleigh JA, Chou SC, Bono EL, Thrall DE, Varia MA. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys 2001;49:569-574
272. van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007;43:1392-1398
273. Seigneuric R, Starmans MH, Fung G, Krishnapuram B, Nuyten DS, van Erk A, et al. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol 2007;83:374-382
274. Chapman JD, Bradley JD, Eary JF, Haubner R, Larson SM, Michalski JM, et al. Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. Int J Radiat Oncol Biol Phys 2003;55:294-301.
275. Rajendran JG, Mankoff DA. Beyond detection: novel applications for PET imaging to guide cancer therapy. J Nucl Med 2007;48:855-856
276. Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987;111:292-304.
277. Bentzen L, Keiding S, Horsman MR, Gronroos T, Hansen SB, Overgaard J. Assessment of hypoxia in experimental mice tumors by [18F] fluoromisonidazole PET and pO2 electrode measurements. Influence of tumor volume and carbogen breathing. Acta Oncol 2002;41:304-312
278. Dubois L, Landuyt W, Haustermans K, Dupont P, Bormans G, Vermaelen P, et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004;91:1947-1954.
279. Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of nonsmall- cell lung cancer: a feasibility study. BMC Cancer 2006;6:51.
280. Rajendran JG, Schwartz DL, O'Sullivan J, Peterson ML, Ng P, Scharnhorst J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006;12:5435-5441
281. Dubois L, Landuyt W, Haustermans K, et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004;91:1947-1954.
282. Troost EG, Bussink J, Kaanders JH, van Eerd J, Peters JP, Rijken PF, et al. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol 2005;76:194-199
283. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson ML, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004; 10:2245-2252
284. Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, et al. Hypoxia-imaging with (18)F-misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol 2007;83:406-410
285. Lucignani G. PET imaging with hypoxia tracers: a must in radiation therapy. Eur J Nucl Med Mol Imaging 2008;35:838-842
286. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18Ffluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys 2007;68:515-521
287. Serganova I, Humm J, Ling C, Blasberg R. Tumor hypoxia imaging. Clin Cancer Res 2006;12:5260-5264
288. Dubois L, Landuyt W, Cloetens L, Bol A, Bormans G, Haustermans K, et al. [(18)F]EF3 is not superior to [(18)F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur J Nucl Med Mol Imaging 2009;36:209-218
289. Graham MA, Senan S, Robin H Jr, Eckhardt M, Lendrem D, Hincks J, et al. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 1997;40:1-10.
290. Davda S, Bezabeh T. Advances in methods for assessing tumor hypoxia in vivo: implications for treatment planning. Cancer Metastasis Rev 2006;25:469-480
291. Pastorekova S, Parkkila S, Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem 2006;42:167-216.
292. Svastova E, Zilka N, Zat'ovicova M, Gibadulinova A, Ciampor F, Pastorek J, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res 2003;290:332-345
293. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-181
294. Supuran CT. Development of small molecule carbonic anhydrase IX inhibitors. BJU Int. 2008 Jun;101 Suppl 4:39-40.
295. Cecchi A, Hulikova A, Pastorek J, Pastorekova S, Scozzafava A, Winum JY, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 2005;48:4834-4841
296. Chrastina A, Zavada J, Parkkila S, Kaluz S, Kaluzova M, Rajcani J, et al. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 2003;105:873-881
297. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007;8:304-310
298. Lin AJ, Cosby LA, Shansky CW, Sartorelli AC. Potential bioreductive alkylating agents. 1.Benzoquinone derivatives. J Med Chem 1973;15:1247-1252
299. Kennedy KA, Teicher BA, Rockwell S, Sartorelli AC. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol 1980;29:1-8.
300. Rockwell S. Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. Int J Cancer 1986;38:229-235
301. Stratford IJ, Adams GE, Godden J, Howells N. Induction of tumor hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. Int J Radiat Biol 1989;55:411-422
302. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, et al. NAD(P)H:quinine oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992;52:797-802.
303. Gan Y, Mo Y, Kalns JE, Lu J, Danenberg K, Danenberg P, et al. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. Clin Cancer Res 2001;7:1313-1319
304. Cowen RL, Patterson AV, Telfer BA, Airley RE, Hobbs S, Phillips RM, et al. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. Mol Cancer Ther 2003;2:901-909
305. Fracasso PM, Sartorelli AC. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells. Cancer Res 1986;46:3939-3944
306. Keyes SR, Rockwell S, Sartorelli AC. Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells. Cancer Res 1987;47:5654-5657
307. Rockwell S, Keyes SR, Sartorelli AC. Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat Res 1988;116:100-113 (Pubitemid 18277669)
308. Haffty BG, Wilson LD, Son YH, Cho EI, Papac RJ, Fischer DB, et al. Concurrent chemoradiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys 2005;61:119-128
309. Walton MI, Smith PJ, Workman P. The role of NAD(P)H: quinone reductase (EC1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun 1991;3:199-206.
310. Robertson N, Haigh A, Adams GE, Stratford IJ. Factors affecting sensitivity to EO9 in rodent and human tumor cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 1994;30A:1013-1019
311. Saunders MP, Jaffar M, Patterson AV, Nolan J, Naylor MA, Phillips RM, et al. The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumor cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochem Pharmacol 2000;59:993-996
312. Loadman PM, Bibby MC, Phillips RM. Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol 2002;137:701-709
313. Puri R, Palit V, Loadman PM, Flannigan M, Shah T, Choudry GA, et al. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J Urol 2006;176:1344-1348
314. Hendricksen K, Gleason D, Young JM, Saltzstein D, Gershman A, Lerner S, et al. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. J Urol 2008;180:116-120
315. Stratford IJ, O'Neill P, Sheldon PW, Silver AR, Walling JM, Adams GE. RSU 1069, a nitroimidazole containing an aziridine group.Bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem Pharmacol 1986;35:105-109
316. Stratford IJ, Stephens MA. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys 1989;16:973-976
317. Stratford IJ, Williams KJ, Cowen RL, Jaffar M. Combining bioreductive drugs and radiation for the treatment of solid tumors. Semin Radiat Oncol 2003;13:42-52.
318. Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, Strafford IJ. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 1997;76:1338-1347
319. Patterson AV, Williams KJ, Cowen RL, Jaffar M, Telfer BA, Saunders M, et al. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiationresistant solid tumors. Gene Ther 2002;9:946-954
320. Horwich A, Holliday SB, Deacon JM, Peckham MJ. A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU- 1069. Br J Radiol 1986;59:1238-1240
321. Bremner JC. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation. Cancer Metastasis Rev 1993;12:177-193
322. Breider MA, Pilcher GD, Graziano MJ, Gough AW. Retinal degeneration in rats induced by Cl-1010, a 2-nitroimidazole radiosensitizer. Toxicol Pathol 1998;26:234-239
323. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002;1:453-458
324. Lunt SJ, Telfer BA, Fitzmaurice RJ, Stratford IJ, Williams KJ. Selective killing of hypoxic cells in primary tumors using tirapazamine reduces metastatic dissemination. Clin Cancer Res 2005;11:4212-4216
325. Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FC, Telfer BA, et al. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 2004;64:1396-1402
326. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol 2007;19:427-442
327. Raleigh SM, Wanogho E, Burke MD, Patterson LH. Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug. Xenobiotica. 1999 Nov;29(11):1115-1122
328. Fitzpatrick B, Mehibel M, Cowen RL, Stratford IJ. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 2008;19:217-224
329. Nishida CR, Ortiz de Montellano PR. Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase. J Med Chem 2008;5:5118-5120
330. McKeown SR, Hejmadi MV, McIntyre IA, McAleer JJ, Patterson LH. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer 1995;72:76-81.
331. McKeown SR, Friery OP, McIntyre IA, Hejmadi MV, Patterson LH, Hirst DG. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer 1996;74:S39-42.
332. Patterson LH, McKeown SR, Ruparelia K, Double JA, Bibby MC, Cole S, et al. Enhancement of chemotherapy and radiotherapy of murine tumors by AQ4N, a bioreductively activated anti-tumor agent. Br J Cancer 2000;82:1984-1990
333. Friery OP, Gallagher R, Murray MM, Hughes CM, Galligan ES, McIntyre IA, et al. Enhancement of the anti-tumor effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br J Cancer 2000;82:1469-1473
334. Gallagher R, Hughes CM, Murray MM, Friery OP, Patterson LH, Hirst DG, et al. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 2001;85:625-629
335. Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet M, et al. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 2008;14:1096-1104
336. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group study 98.02. J Clin Oncol 2006;24:2098-2104
337. Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res 2003;9:5714-5720
338. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. Reductive metabolism of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257). Oncol Res 2003;14:21-29
339. Papadopoulou MV, Ji M, Bloomer WD. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother Pharmacol 2001;48:160-168
340. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 4-[3-(2-Nitro-1- imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine. Oncol Res 2001;12:325-333
341. Papadopoulou MV, Ji M, Bloomer WD. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine. Oncol Res 2002;13:47-54.
342. Papadopoulou MV, Ji M, Ji X, Bloomer WD. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine. Cancer Chemother Pharmacol 2002;50: 291-298
343. Papadopoulou MV, Ji X, Bloomer WD. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo. J Exp Ther Oncol 2006;5:261-272
344. Wilson WR, Pullen SM, Degenkolbe A, Ferry DM, Helsby NA, Hicks KO, Atwell GJ, Yang S, Denny WA, Patterson AV. Water-soluble dinitrobenzamide mustard phosphate pre-prodrugs as hypoxic cytotoxins. Eur J Cancer 2004;Suppl. 2(8):151.
345. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 2007;13:3922-3932
346. Danson S, Johnson P, Ward T, Dawson M, Denneny O, Watson A. et al. Final results of a phase I clinical trial of the bioreductive drug RH1. J Clin Oncol 2007;25(18S):2514.
347. Yan C, Kepa JK, Siegel D, Stratford IJ, Ross D. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1). Mol Pharmacol. 2008 Dec;74(6):1657-1665 Epub 2008 Sep 15.
348. Loadman PM, Phillips RM, Lim LE, Bibby MC. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl- 3-(hydroxymethyl)-6-methyl- 1,4-benzoquinone), in mice. Biochem Pharmacol 2000;59:831-837
349. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-189
350. Pastorekova S, Pastorek, J. Cancer-related carbonic anhydrase isozymes. In: Supuran CT, Scozzafava A, Conway J,eds. Carbonic Anhydrase-Its Inhibitors and Activators. Boca Raton, FL: CRC Press, 2004: 253-280
351. Hilvo M, Monti SM, De Simone G, Supuran CT, Parkkila S. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 2008;283:27799-27809
352. Winum JY, Rami M, Scozzafava A, Montero JL, Supuran C. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev 2008;28:445-463
353. Thiry A, Supuran CT, Masereel B, Dogné JM. Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem 2008;51:3051-3056
354. Cecchi A, Supuran CT. Fluorescence- and spin-labeled carbonic anhydrase inhibitors. Curr Pharm Des 2008;14:699-707.
355. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004;19:199-229.
356. Menchise V, De Simone G, Alterio V, Di Fiore A, Pedone C, Scozzafava A, et al. Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J Med Chem 2005;48:5721-5727
357. Alterio V, Vitale RM, Monti SM, Pedone C, Scozzafava A, Cecchi A, et al. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J Am Chem Soc 2006;128:8329-8335
358. Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14:217-223
359. Garaj V, Pucetti L, Fasolis G, Winum J-Y, Montero J-L, Scozzafava A, et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/ tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg Med Chem Lett 2004;14:5427-5433 (Pubitemid 39348939)
360. De Simone G, Vitale RM, Di Fiore A, Pedone C, Scozzafava A, Montero JL, et al. Carbonic anhydrase inhibitors: hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem 2006;49:5544-5551
361. Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 2004;64:6160-6165
362. Oosterwijk E. Carbonic anhydrase IX: historical and future perspectives. BJU Int 2008;101(Suppl 4):2-7.
363. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep 2005;7:109-115
364. Görlach A, Kietzmann T. Superoxide and derived reactive oxygen species in the regulation of hypoxia-inducible factors. Methods in Enzymology. 2007;435:421-446
365. Kietzmann T, Görlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression, Semin Cell Dev Biol. 2005; 16:474-486
366. Toffoli S, Michiels C. Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J. 2008;275:2991-3002.
367. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8:425-437
368. Nanduri J, Yuan G, Kumar GK, Semenza GL, Prabhakar NR. Transcriptional responses to intermittent hypoxia. Respir Physiol Neurobiol. 2008 164:277-281
369. Dewhirst MW. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res. 2007;67:854-855
370. Martínez-Sánchez G, Giuliani A. Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development. J Exp Clin Cancer Res. 2007;26:39-50.
371. Bell EL, Chandel NS. Mitochondrial oxygen sensing: regulation of hypoxiainducible factor by mitochondrial generated reactive oxygen species. Essays Biochem. 2007;43:17-27.
372. Cash TP, Pan Y, Simon MC. Reactive oxygen species and cellular oxygen sensing. Free Radic Biol Med. 2007;43:1219-1225
373. Guzy RD, Schumacker PT. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol. 2006;91:807-819
374. Wang J, Yi J. Cancer cell killing via ROS: To increase or decrease, that is a question. Cancer Biol Ther. 2008;7:1875-1884
375. Matsumoto K, Subramanian S, Murugesan R, Mitchell JB, Krishna MC.